Vincent T. H. B. M. Smit

Vincent T. H. B. M. Smit

Auto-generated profile, based on publicly available information

Vincent T. H. B. M. Smit

Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2023 in JCO Global Oncology
Verified
Journal Article
Open access
AHAnne Sophie V.M. Van Den Heerik
Anne Sophie V.M. Van Den Heerik
NHNatalja T. Ter Haar
Natalja T. Ter Haar
LVLisa Vermij
Lisa Vermij
JJJan Jobsen
Jan Jobsen
MBMariël Brinkhuis
Mariël Brinkhuis
TBTjalling Bosse
Tjalling Bosse
PURPOSE: Detection of 11 pathogenic variants in the POLE gene in endometrial cancer (EC) is critically important to identify women with a good prognosis and reduce overtreatment. Currently, POLE status is determined by DNA sequencing, which can be expensive, relatively time-consuming, and unavailable in hospitals without specialized equipment and personnel. This may hamper the implementation of POLE-testing in clinical practice. To overcome this, we developed and validated a rapid, low-cost POLE hotspot test by a quantitative polymerase chain reaction (qPCR) assay, QPOLE. MATERIALS AND METHODS: Primer and fluorescence-labeled 5′-nuclease probe sequences of the 11 established pathogenic POLE mutations were designed. Three assays, QPOLE-frequent for the most common mutations and QPOLE-rare-1 and QPOLE-rare-2 for the rare variants, were developed and optimized using DNA extracted from formalin-fixed paraffin-embedded tumor tissues. The simplicity of the design enables POLE status assessment within 4-6 hours after DNA isolation. An interlaboratory external validation study was performed to determine the practical feasibility of this assay. RESULTS: Cutoffs for POLE wild-type, POLE-mutant, equivocal, and failed results were predefined on the basis of a subset of POLE mutants and POLE wild-types for the internal and external validation. For equivocal cases, additional DNA sequencing is recommended. Performance in 282 EC cases, of which 99 were POLE-mutated, demonstrated an overall accuracy of 98.6% (95% CI, 97.2 to 99.9), a sensitivity of 95.2% (95% CI, 90.7 to 99.8), and a specificity of 100%. After DNA sequencing of 8.8% equivocal cases, the final sensitivity and specificity were 96.0% (95% CI, 92.1 to 99.8) and 100%. External validation confirmed feasibility and accuracy. CONCLUSION: QPOLE is a qPCR assay that is a quick, simple, and reliable alternative for DNA sequencing. QPOLE detects all pathogenic variants in the exonuclease domain of the POLE gene. QPOLE will make low-cost POLE-testing available for all women with EC around the globe.

1 February 2015 in Fertility and Sterility
Verified
Journal Article
Closed access
EHEllen J. Hoekman
Ellen J. Hoekman
VSVincent T.H.B.M. Smit
Vincent T.H.B.M. Smit
TFTimothy P. Fleming
Timothy P. Fleming
LLLeonie A. Louwe
Leonie A. Louwe
GFGert Jan Fleuren
Gert Jan Fleuren
CHCarina G.J.M. Hilders
Carina G.J.M. Hilders

1 March 2016 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
MGMignon D.J.M. van Gent
Mignon D.J.M. van Gent
ANAlina R. Nicolae-Cristea
Alina R. Nicolae-Cristea
CKCor de Kroon
Cor de Kroon
EOElisabeth M. Osse
Elisabeth M. Osse
MKMarjolein J. Kagie
Marjolein J. Kagie
TBTjalling Bosse
Tjalling Bosse

11 June 2025 in Cellular Oncology
Verified
Journal Article
Open access
PDF file
Noel de MirandaNoel de Miranda
Noel de Miranda
VSVincent T. H. B. M. Smit
Vincent T. H. B. M. Smit
MPManon van der Ploeg
Manon van der Ploeg
JWJelle Wesseling
Jelle Wesseling
JNJacques Neefjes
Jacques Neefjes
The relationship between bacterial activity and tumorigenesis has gained attention in recent years, complementing the well-established association between viruses and cancer. A recent study employed immunodetection of lipopolysaccharide (LPS) to demonstrate the presence of intracellular bacteria within cancer cells across various cancer types, including breast cancer. The authors proposed that these bacteria might play a role in tumor development. We sought to replicate these findings using the same experimental methods on an independent cohort of breast cancer cases. Our analysis of 129 samples revealed no evidence of LPS expression within cancer cells. Instead, LPS immunoreactivity was observed in ducts or immune cells, specifically macrophages, as expected. These discrepancies in LPS immunodetection warrant caution in interpreting the original findings, and further research is needed to clarify the potential role of intracellular bacteria in cancer development.

28 August 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
Noel de MirandaNoel de Miranda
Noel de Miranda
VSVincent Thbm Smit
Vincent Thbm Smit
MPManon van der Ploeg
Manon van der Ploeg
JWJelle Wesseling
Jelle Wesseling
JNJacques Neefjes
Jacques Neefjes
The association between bacterial activity and tumorigenesis has gained attention in recent years, alongside the well-established link between viruses and cancer. A recent study proposed the presence of intracellular bacteria in cancer cells, particularly in melanomas and breast cancers, with detectable bacterial DNA. The authors suggested that these bacteria contribute to the tumors’ development. We sought to replicate these findings using the same experimental methods on different tissue microarrays. Our investigation included 129 breast cancer samples, but we found no evidence of LPS expression within cancer cells. Instead, LPS immunoreactivity was observed in ducts or immune cells, specifically macrophages. The discrepancies in LPS staining warrant caution in interpreting the reported observations, and further research is needed to elucidate the potential role of intracellular bacteria in cancer development.

9 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
NBNikki van Den Berg
Nikki van Den Berg
LSLydia Schoenpflug
Lydia Schoenpflug
NHNanda Horeweg
Nanda Horeweg
SVSarah Volinsky-Fremond
Sarah Volinsky-Fremond
JBJurriaan Barkey-Wolf
Jurriaan Barkey-Wolf
TBTjalling Bosse
Tjalling Bosse
POLE sequencing for somatic mutations ( POLE mut) guides adjuvant therapy in endometrial cancer (EC), but cost and infrastructural considerations lead to limited uptake. Omission of POLE testing leads to unnecessary exposure to radiotherapy and/or chemotherapy. We developed POLARIX, a multiple instance deep learning model with attention pooling, which predicts POLE mutation status from routine hematoxylin and eosin whole-slide images (WSIs). Trained on 2,238 cases from eleven EC cohorts, POLARIX showed clinical-grade discrimination across three external cohorts (Pooled: AUC=0.95, 95% CI: 0.91–0.98; n =68/481 POLE mut/ POLE wt). Attention maps highlight POLE morphologies. Clinical applicability is demonstrated using predefined thresholds based on three resource scenarios. The most sensitive threshold (“Low”) yields a test reduction of 77% (73%-81%) (sensitivity: 93% (85%-99%), specificity: 89% (87%-92%)). POLARIX is an interpretable and cost-efficient approach to reduce POLE testing in women with endometrial cancer, broadening access to precision oncology.